TRU-SENTIMENT · DeltaNeutral
GRAL Trading Analysis - 09/30/2026 04:11 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
GRAL (GRAIL Inc. Common Stock) at $141.91. True Sentiment Bullish, delta 40-60 call 82% / put 18%, call $1,722,010 vs put $373,040. RSI 93.2.
- Symbol
- GRAL
- Price
- $141.91
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- medium
- Published
- 2026-09-30 16:11:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis: Delta 40–60 Options
Call volume: $1,722,010.00 (82.20%)
Put volume: $373,040.00 (17.80%)
Total analyzed: $2,095,050.00
The options flow is classified as Bullish. Call contracts totaled 812, compared with 215 put contracts. There were 23 call trades versus 9 put trades, and the directional filter identified 32 qualifying contracts out of 354 total options analyzed.
The call-to-put dollar-volume ratio is approximately 4.62:1, indicating substantially greater directional bullish participation in the supplied dataset. This positioning suggests that market participants are expecting continued strength or are seeking upside exposure into the November 20, 2026 expiration.
Key Statistics: GRAL
Fundamental Snapshot
Valuation
| EPS (trailing 12 mo) | $-9.76 |
| Market cap | $6.31B |
| Shares outstanding | 44.7M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| 52-week low | $41.50 |
| 52-week high | $127.67 |
| Historical volatility | 99.8% |
Ownership & trading
| Institutional ownership | 36.7% |
| Average daily volume | 1.3M sh |
Reported figures; no analyst estimates.
📈 Analysis
GRAL Trading Analysis
GRAL’s supplied data shows a powerful, highly volatile upward move, with the latest minute-bar close at $141.91 and the prior daily indicator close at $135.49. Momentum remains strongly positive, but the RSI is deeply overbought and the stock has moved beyond the reported 30-day high shown in the daily dataset. Options sentiment is also bullish, although the options-spread recommendation file cautions that technicals and options sentiment are not yet fully aligned.
News Headlines & Context
The embedded dataset does not contain company-specific news headlines, filings, earnings dates, or verified event announcements. Therefore, no specific external news claim can be reliably attributed to GRAL from the information provided. The following are monitoring themes rather than confirmed headlines:
- Potential clinical or commercial catalyst: A biotechnology stock can react sharply to trial updates, regulatory decisions, partnership announcements, or changes to commercialization expectations. No such event is included in the supplied data.
- Potential earnings catalyst: Future earnings, guidance, cash-burn updates, and pipeline commentary could materially affect valuation. The supplied fundamentals show trailing EPS of -$9.76, making profitability and forward guidance particularly important.
- Volatility and price-discovery risk: The stock’s supplied historical volatility is 99.84%, and the recent price advance has been unusually rapid. Additional news could produce outsized moves in either direction.
- Financing or dilution risk: The dataset provides no debt, cash-flow, cash-balance, or financing information. For a loss-making biotechnology company, future capital needs can be an important market catalyst, but no conclusion can be made from the supplied data.
These contextual risks are consistent with the extreme momentum and volatility in the supplied market data, but they should not be interpreted as confirmed GRAL-specific events.
Fundamental Analysis
| Metric | Supplied value | Interpretation |
|---|---|---|
| Market capitalization | $6.31 billion | Large valuation relative to the supplied loss-making EPS profile, although market capitalization alone does not determine valuation. |
| Trailing EPS | -$9.76 | Negative trailing profitability. |
| Trailing P/E | Not available | A traditional P/E cannot be calculated because trailing EPS is negative. |
| Forward P/E | Not available | No forward earnings estimate is supplied. |
| PEG ratio | Not available | No PEG ratio or growth forecast is supplied; peer comparison is therefore not possible from the embedded data. |
| Institutional ownership | 36.71% | Meaningful institutional participation, but this does not establish a current accumulation trend. |
| Historical volatility | 99.84% | Extremely high volatility and substantial forecast uncertainty. |
| Average volume | 1.29 million shares | Reported average volume, compared with the latest daily volume of 727,941 shares in the supplied history. |
Earnings, Growth, and Valuation
Revenue growth, gross margin, operating margin, net margin, debt-to-equity, return on equity, free cash flow, and recent earnings trends are not provided. As a result, no YoY revenue trend or margin analysis can be calculated strictly from the embedded data.
Trailing EPS is -$9.76, while both trailing and forward P/E ratios are unavailable. The reported PEG ratio is also unavailable. Consequently, there is no defensible numerical P/E or PEG comparison against a biotechnology sector or peer group in the supplied dataset.
Fundamental Strengths and Concerns
- Potential strength: Market capitalization of $6.31 billion and institutional ownership of 36.71% indicate substantial market interest.
- Primary concern: Negative trailing EPS of -$9.76 means the current valuation cannot be supported by conventional trailing earnings in the supplied data.
- Missing information: Debt/equity, free cash flow, cash position, revenue growth, margins, ROE, analyst opinions, and price targets are all unavailable.
- Technical-fundamental divergence: Price and options flow are bullish, but the supplied earnings profile does not provide fundamental confirmation.
Current Market Position
GRAL rose from a daily close of $135.49 on September 29, 2026 to a latest minute-bar close of $141.91 on September 30, 2026. The latest five minute bars show trading between $141.56 and $142.90, followed by a close at $141.91. This indicates strong intraday momentum, but also a pause near the top of the recent range.
The early portion of the September 30 session was highly volatile. The first supplied bar opened at $132.75 and traded between $132.51 and $135.47, while the second bar reached $137.99. The latest price is therefore well above the early-session range, but the stock is also trading at a significant premium to the prior daily close.
Technical Analysis
Technical Indicators
Interactive charts load with JavaScript. This text is the crawlable summary.